0000891293-22-000008.txt : 20220331 0000891293-22-000008.hdr.sgml : 20220331 20220331160424 ACCESSION NUMBER: 0000891293-22-000008 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20220331 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20220331 DATE AS OF CHANGE: 20220331 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CTI BIOPHARMA CORP CENTRAL INDEX KEY: 0000891293 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911533912 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-28386 FILM NUMBER: 22792370 BUSINESS ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 BUSINESS PHONE: 2062827100 MAIL ADDRESS: STREET 1: 3101 WESTERN AVENUE STREET 2: SUITE 800 CITY: SEATTLE STATE: WA ZIP: 98121 FORMER COMPANY: FORMER CONFORMED NAME: CELL THERAPEUTICS INC DATE OF NAME CHANGE: 19960321 8-K 1 ctic-20220331.htm 8-K ctic-20220331
0000891293false00008912932022-03-312022-03-31

 UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 31, 2022
 
CTI BIOPHARMA CORP.
(Exact name of registrant as specified in its charter)
 
Delaware000-2838691-1533912
(State or other jurisdiction of
incorporation or organization)
(Commission
File Number)
(I.R.S. Employer
Identification Number)
3101 Western Avenue, Suite 800
Seattle, Washington 98121
(Address of principal executive offices)
Registrant’s telephone number, including area code: (206282-7100
Not applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.001CTICNasdaq Capital Market



Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.




Item 2.02. Results of Operations and Financial Condition.

On March 31, 2022, CTI BioPharma Corp. issued a press release announcing its financial results for the quarter and year ended December 31, 2021 and certain other information. The full text of the press release is set forth in Exhibit 99.1 hereto. The information in this Current Report on Form 8-K and the attached exhibit are furnished to, but not filed with, the Securities and Exchange Commission.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits

Pursuant to the rules and regulations of the Securities and Exchange Commission, the attached exhibit is deemed to have been furnished to, but not filed with, the Securities and Exchange Commission:
Exhibit
No.
DescriptionLocation
99.1Furnished herewith.
104Cover Page Interactive Data File (embedded within the Inline XBRL document)






SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CTI BIOPHARMA CORP.

Date: March 31, 2022

By:

/s/ David H. Kirske
David H. Kirske
Chief Financial Officer




EX-99.1 2 ex991earningsreleaseq42021.htm EX-99.1 Document

Exhibit 99.1
cti_logoxrgbx1501a.jpg


CTI BioPharma Reports Fourth Quarter and Full Year 2021 Financial Results

– VONJOTM (pacritinib) Approved by FDA for the Treatment of Adult Myelofibrosis Patients with Myelofibrosis and Thrombocytopenia; Commercial Launch Underway –

– $60 Million Payment from DRI Healthcare Trust Triggered by FDA Approval under the Terms of the Previously Announced Debt and Royalty Transaction –



SEATTLE, Mar. 31, 2022 - CTI BioPharma Corp. (Nasdaq: CTIC) today reported its financial results for the fourth quarter and full year ended December 31, 2021.

“VONJO’s recent FDA approval establishes a new standard of care for myelofibrosis patients suffering from cytopenic myelofibrosis. With a fully funded commercial launch following the debt and royalty transaction with DRI, we are pleased to provide these patients with a new, efficacious, and safe treatment option,” said Adam R. Craig, M.D., Ph.D., President and Chief Executive Officer of CTI Biopharma. “We believe the launch of VONJO positions CTI for sustained growth as we work towards our mission to make a meaningful impact on the lives of patients with blood-related cancers.”

Fourth Quarter Financial Results
Operating loss was $35.4 million and $95.3 million for the three months and year ended December 31, 2021, respectively, compared to operating loss of $14.8 million and $47.8 million for the corresponding periods in 2020. The increase in operating loss for the three months and year ended December 31, 2021 as compared to the comparable periods in 2020 resulted primarily from increases in selling, general and administrative activities related to the growth in our commercial infrastructure and commercial-launch readiness activities in support of commercialization of VONJO, as well as research and development activities related to the continued development of pacritinib.

Net loss for the three months ended December 31, 2021 was $36.8 million, or $0.38 for basic and diluted loss per share, compared to net loss of $15.0 million, or $0.20 for basic and diluted loss per share, for the same period in 2020. Net loss for the year ended December 31, 2021 was $97.9 million, or $1.09 for basic and diluted loss per share, compared to net loss of $52.5 million, or $0.74 for basic and diluted loss per share, for the same period in 2020.




As of December 31, 2021, cash and cash equivalents totaled $65.4 million. As of December 31, 2020, cash, cash equivalents and short-term investments totaled $52.5 million. We expect our current cash and cash equivalents, together with $60.0 million received from DRI Healthcare Trust following FDA approval of VONJO, will enable us to fund our operations into the fourth quarter of 2022.

About Myelofibrosis
Myelofibrosis is bone marrow cancer that results in formation of fibrous scar tissue and can lead to thrombocytopenia and anemia, weakness, fatigue and an enlarged spleen and liver. Within the United States, there are approximately 21,000 patients with myelofibrosis, 7,000 of which have severe thrombocytopenia (defined as blood platelet counts of less than 50 x109/L). Severe thrombocytopenia is associated with poor survival and high symptom burden and can occur as a result of disease progression or from drug toxicity with other JAK2 inhibitors, such as JAKAFI and INREBIC.

About CTI BioPharma Corp.
We are a commercial biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI has one FDA-approved product VONJOTM (pacritinib), a JAK2, IRAK1 and CSF1R inhibitor that spares JAK1. VONJO is approved for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a baseline platelet count of <50×109/L. CTI is conducting the Phase 3 PACIFICA study of VONJO in patients with myelofibrosis and severe thrombocytopenia as a post-marketing requirement. CTI is headquartered in Seattle, Washington.

VONJOTM is a trademark of CTI BioPharma Corp.

Forward-Looking Statements
Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on current assumptions that involve risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from those expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: our ability to commercially launch VONJO; our expectations regarding the completion and outcome of our PACIFICA Phase 3 trial; the accuracy of our assumptions regarding our planned expenditures and sufficiency of our cash to fund operations, including the commercial launch of VONJO; risks and uncertainties related to the COVID-19 pandemic as it relates to our operations and ongoing clinical trials; and those risks more fully discussed in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021 and subsequent quarterly reports on Form 10-Q. These forward-



looking statements speak only as of the date hereof and we assume no obligation to update these forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements. “CTI BioPharma” and the CTI BioPharma logo are registered trademarks or trademarks of CTI BioPharma Corp. in various jurisdictions. All other trademarks belong to their respective owner.

CTI BioPharma Investor Contacts:
Argot Partners
+212-600-1902
cti@argotpartners.com

(tables follow)




CTI BioPharma Corp.
Condensed Consolidated Statements of Operations
(In thousands, except per share amounts)
(unaudited)
Three Months Ended
 December 31,
Twelve Months Ended
December 31,
 2021202020212020
Operating costs and expenses:   
Research and development$10,682 $9,486 $39,136 $25,943 
Selling, general and administrative24,693 5,310 56,196 17,626 
Other operating expenses— — — 4,200 
Total operating costs and expenses35,375 14,796 95,332 47,769 
Loss from operations(35,375)(14,796)(95,332)(47,769)
Non-operating expense:   
Interest expense, net (1,408)(205)(2,415)(828)
Other non-operating expense(5)(1)(161)(3,854)
Total non-operating expense(1,413)(206)(2,576)(4,682)
Net loss$(36,788)$(15,002)$(97,908)$(52,451)
Basic and diluted net loss per common share $(0.38)$(0.20)$(1.09)$(0.74)
Shares used in calculation of basic and diluted net loss per common share:97,663 74,640 90,117 71,141 

Balance Sheet Data (unaudited):(amounts in thousands)
December 31,December 31,
20212020
Cash and cash equivalents $65,446 $40,394 
Short-term investments— 12,057 
Working capital1,728 37,287 
Total assets72,434 58,241 
Current portion of long-term debt47,380 4,455 
Total stockholders' equity3,767 40,029 



EX-101.SCH 3 ctic-20220331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ctic-20220331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Pre-commencement Tender Offer Pre-commencement Tender Offer Amendment Flag Amendment Flag Entity Address, State or Province Entity Address, State or Province Entity Tax Identification Number Entity Tax Identification Number Title of 12(b) Security Title of 12(b) Security Entity File Number Entity File Number Written Communications Written Communications Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Trading Symbol Trading Symbol Document Period End Date Document Period End Date Soliciting Material Soliciting Material Document Type Document Type City Area Code City Area Code Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name Entity Address, Address Line Two Entity Address, Address Line Two Local Phone Number Local Phone Number Entity Address, City or Town Entity Address, City or Town Cover [Abstract] Cover [Abstract] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key EX-101.PRE 5 ctic-20220331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 6 cti_logoxrgbx1501a.jpg begin 644 cti_logoxrgbx1501a.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.1
Cover Page
Mar. 31, 2022
Cover [Abstract]  
Document Type 8-K
Document Period End Date Mar. 31, 2022
Entity Registrant Name CTI BIOPHARMA CORP.
Entity Incorporation, State or Country Code DE
Entity File Number 000-28386
Entity Tax Identification Number 91-1533912
Entity Address, Address Line One 3101 Western Avenue
Entity Address, Address Line Two Suite 800
Entity Address, City or Town Seattle
Entity Address, State or Province WA
Entity Address, Postal Zip Code 98121
City Area Code 206
Local Phone Number 282-7100
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001
Trading Symbol CTIC
Entity Emerging Growth Company false
Entity Central Index Key 0000891293
Amendment Flag false

XML 8 ctic-20220331_htm.xml IDEA: XBRL DOCUMENT 0000891293 2022-03-31 2022-03-31 0000891293 false 8-K 2022-03-31 CTI BIOPHARMA CORP. DE 000-28386 91-1533912 3101 Western Avenue Suite 800 Seattle WA 98121 206 282-7100 false false false false Common Stock, par value $0.001 CTIC false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 1 22 1 false 0 0 false 0 false false R1.htm 0001001 - Document - Cover Page Sheet http://www.ctibiopharma.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports ctic-20220331.htm ctic-20220331.xsd ctic-20220331_lab.xml ctic-20220331_pre.xml ex991earningsreleaseq42021.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ctic-20220331.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "ctic-20220331.htm" ] }, "labelLink": { "local": [ "ctic-20220331_lab.xml" ] }, "presentationLink": { "local": [ "ctic-20220331_pre.xml" ] }, "schema": { "local": [ "ctic-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ctic", "nsuri": "http://www.ctibiopharma.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctic-20220331.htm", "contextRef": "iefba77ddd83a42d09ffec5fbdbc575c2_D20220331-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001001 - Document - Cover Page", "role": "http://www.ctibiopharma.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "ctic-20220331.htm", "contextRef": "iefba77ddd83a42d09ffec5fbdbc575c2_D20220331-20220331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ctibiopharma.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r4": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r5": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0000891293-22-000008-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000891293-22-000008-xbrl.zip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